ZA949350B - Aqueous prolonged release formulation - Google Patents

Aqueous prolonged release formulation

Info

Publication number
ZA949350B
ZA949350B ZA949350A ZA949350A ZA949350B ZA 949350 B ZA949350 B ZA 949350B ZA 949350 A ZA949350 A ZA 949350A ZA 949350 A ZA949350 A ZA 949350A ZA 949350 B ZA949350 B ZA 949350B
Authority
ZA
South Africa
Prior art keywords
bovine somatotropin
aqueous
release formulation
prolonged release
circulatory system
Prior art date
Application number
ZA949350A
Other languages
English (en)
Inventor
Michael J Hageman
Margaret L Possert
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ZA949350B publication Critical patent/ZA949350B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA949350A 1994-01-25 1994-11-24 Aqueous prolonged release formulation ZA949350B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18657294A 1994-01-25 1994-01-25

Publications (1)

Publication Number Publication Date
ZA949350B true ZA949350B (en) 1996-05-24

Family

ID=22685468

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA949350A ZA949350B (en) 1994-01-25 1994-11-24 Aqueous prolonged release formulation

Country Status (18)

Country Link
US (2) US6471977B1 (es)
EP (1) EP0741579B1 (es)
JP (1) JPH09508118A (es)
KR (1) KR100355517B1 (es)
CN (1) CN1139385A (es)
AT (1) ATE187077T1 (es)
AU (1) AU699746B2 (es)
CA (1) CA2178610A1 (es)
DE (1) DE69513635T2 (es)
DK (1) DK0741579T3 (es)
ES (1) ES2139881T3 (es)
GR (1) GR3032727T3 (es)
LV (1) LV12627B (es)
MX (1) MX9602943A (es)
NZ (1) NZ278770A (es)
SI (1) SI0741579T1 (es)
WO (1) WO1995019787A1 (es)
ZA (1) ZA949350B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA949350B (en) * 1994-01-25 1996-05-24 Upjohn Co Aqueous prolonged release formulation
WO1997025057A1 (en) 1996-01-11 1997-07-17 Pharmacia & Upjohn Company Aqueous prolonged release formulation
US7319032B2 (en) * 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
WO2022124914A1 (en) 2020-12-08 2022-06-16 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118380A (en) 1977-07-25 1978-10-03 Ayerst, Mckenna & Harrison Limited Decapeptide analogs of somatostatin
DE3484584D1 (de) 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
US4774091A (en) 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
US4985404A (en) 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
EP0193917A3 (en) 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
PT83095B (en) 1985-07-30 1987-12-23 Int Minerals & Chem Corp Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
US4977140A (en) 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4857506A (en) 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
US4863736A (en) * 1987-03-16 1989-09-05 Monsanto Company Somatotropin prolonged release
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
EP0353045B1 (en) 1988-07-26 1995-11-15 Rutgers, The State University of New Jersey Devices and methods for growth promotion in poultry roasters
EP0374120A3 (en) 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
US5015627A (en) 1990-07-20 1991-05-14 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
US5169834A (en) 1990-11-30 1992-12-08 American Cyanamid Company Compositions and method for reducing vial breakage during lyophilization
US5198422A (en) 1992-06-11 1993-03-30 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
ZA949350B (en) * 1994-01-25 1996-05-24 Upjohn Co Aqueous prolonged release formulation

Also Published As

Publication number Publication date
US20030220242A9 (en) 2003-11-27
AU1521395A (en) 1995-08-08
SI0741579T1 (en) 2000-04-30
EP0741579A1 (en) 1996-11-13
ATE187077T1 (de) 1999-12-15
JPH09508118A (ja) 1997-08-19
US6699490B2 (en) 2004-03-02
DE69513635T2 (de) 2000-05-31
GR3032727T3 (en) 2000-06-30
CN1139385A (zh) 1997-01-01
KR100355517B1 (ko) 2003-03-04
DE69513635D1 (de) 2000-01-05
LV12627B (en) 2001-08-20
US6471977B1 (en) 2002-10-29
LV12627A (lv) 2001-03-20
CA2178610A1 (en) 1995-07-27
MX9602943A (es) 1997-06-28
EP0741579B1 (en) 1999-12-01
WO1995019787A1 (en) 1995-07-27
DK0741579T3 (da) 2000-05-15
US20030092625A1 (en) 2003-05-15
NZ278770A (en) 1997-09-22
ES2139881T3 (es) 2000-02-16
AU699746B2 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
NZ294464A (en) Stable, aqueous formulation having high biological alpha-type interferon activity buffered from 4.5 to 7.1 and comprising chelating agent and a polyoxyethylene sorbitan monooleate, formulation free from human blood-derived products
MY125556A (en) Aqueous formulations of peptide
EP0696208A4 (en) ORAL DELIVERY FORM AND METHOD
FI970298A0 (fi) DHA:n käyttö farmaseuttisena koostumuksena
IL89276A0 (en) Human relaxin formulation
HUT66429A (en) Compositions for treating osteoporosis
ES2114851T3 (es) Utilizacion de composiciones de liberacion sostenida que contienen gnrh, lhrh o derivados de las mismas.
TW264386B (es)
ES2100354T3 (es) Sistema de implante nervioso.
HK1016083A1 (en) Aqueous prolonged release formulation
ZA949350B (en) Aqueous prolonged release formulation
EP0572494A4 (en) Composition for use in transdermal administration
GR3029319T3 (en) Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity
GB8603964D0 (en) Compositions
ES8800040A1 (es) Procedimiento para la obtencion de una composicion farmaceutica de liberacion retardada a base de 9,10-dihidro-alcaloides.
GR3032546T3 (en) Use of azoles as virucidal agents in solutions of biologically active proteins
EP0539516A4 (es)
HK1003422A1 (en) A method of treating liver disease and like indications with vasodilating agents
IL95059A0 (en) Composition for administration of nitrofurantoin
IL95924A0 (en) Composition for controlled delivery of biologically active agents
BG49848A1 (en) Cytocinine means
RU92015628A (ru) Состав для дезинфекции объектов пчеловодства